A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

MKC253 Inhalation Powder

Inhalation Powder, prandial

DRUG

Technosphere Inhalation Powder

Inhalation Powder, prandial

DRUG

subcutaneous injection

10µg Exenatide, prandial

Trial Locations (1)

University Medical Centre Groningen, Zuidlaren